Humana Inc. (HUM)
Earnings Preview: Humana (HUM) Q1 Earnings Expected to Decline
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is It Too Late to Buy Humana Inc (HUM) After 3.3% Rally? GF Value Says Undervalued
On April 21, 2026, Humana Inc (HUM) shares rose 3.3% today, closing at $217.36. The stock has seen significant movement over the past month, gaining 28.6%, alth
Humana Bets on Pharmacists to Lift Chronic Care Outcomes
HUM taps pharmacists via a value-based program in Ohio to boost hypertension and diabetes outcomes while aiming to curb costs and improve care access.
Humana (HUM) Moves 7.9% Higher: Will This Strength Last?
Humana (HUM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
US health insurer stocks pop on Medicare payment hike
Shares of US health insurers surged on Tuesday morning after the Trump administration announced that Medicare Advantage payments will increase more than initially projected. The Centers for Medicare & Medicaid Services (CMS), which oversees government-funded health programs including Medicare, said it will raise payments to private Medicare insurers by a net average of 2.48% in 2027.
Insurance Stocks Soars on 2027 Medicare Advantage Rates
Healthcare stock Humana Inc (NYSE:HUM) is leading its sector today, up 10.7% to trade at $202.41, after the Center for Medicare & Medicaid Services completed its proposed payment increase to privately run Medicare Advantage plans for 2027.
Reasons Behind Holding Humana Shares: What Investors Need to Know
HUM's value-based care model, Medicare Advantage growth and CenterWell expansion drive momentum despite cost pressures and a 36% stock decline.
Why Is Humana (HUM) Down 8.5% Since Last Earnings Report?
Humana (HUM) reported earnings 30 days ago. What's next for the stock?
Humana Inc. (HUM) Presents at Leerink Global Healthcare Conference 2026 Transcript
Humana Inc. (HUM) Presents at Leerink Global Healthcare Conference 2026 Transcript
Humana Long Climb: Navigating The 4-STAR Recovery And The J-Curve
Humana faces severe headwinds from rising medical costs and a dramatic drop in 4-STAR Medicare Advantage membership, pressuring margins and profitability. Management is implementing STAR mitigation efforts and aggressive CenterWell and Medicaid expansion, targeting a turnaround by bonus year 2028. Despite near-term margin compression and operational risk, my DCF-based valuation of $330 per share suggests HUM is undervalued and presents a buying opportunity.
Is the Options Market Predicting a Spike in Humana Stock?
Investors need to pay close attention to Humana stock based on the movements in the options market lately.
Humana Incurs Q4 Loss, Revenues Up Y/Y on CenterWell Unit Strength
HUM incurs a wider year-over-year loss in Q4 due to rising costs, weaker investment income and membership declines. Yet, revenues climb 12% on CenterWell strength.
